Dumas Jacques 4
4 · TETRAPHASE PHARMACEUTICALS INC · Filed Aug 24, 2017
Insider Transaction Report
Form 4
Dumas Jacques
Chief ScientificOfficer
Transactions
- Exercise/Conversion
Common Stock
2017-08-22$3.69/sh+17,500$64,575→ 17,500 total - Sale
Common Stock
2017-08-22$6.00/sh−17,500$105,000→ 0 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2017-08-22−17,500→ 122,500 totalExercise: $3.69Exp: 2027-01-29→ Common Stock (17,500 underlying)
Footnotes (2)
- [F1]The exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
- [F2]Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/31/2021.